Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORIOSA: Mirvetuximab soravtansine + bevacizumab vs bevacizumab as maintenance in FRα‑high platinum‑sensitive recurrent ovarian cancer
jRCT2011240046Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Mirvetuximab soravtansine + bevacizumab with Bevacizumab monotherapy (2 arms). Primary endpoint: Progression-free survival (PFS). Started Mar 2023; status: active, not recruiting.
02
Drugs
mirvetuximab soravtansinebevacizumab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on jRCT2011240046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011240046.